Rilpivirine-emtricitabine-tenofovir disoproxil (Eviplera) for the indication ‘infection with HIV-1’

For the treatment of adult, therapy-naive patients infected with HIV-1 and with a virus concentration ≤ 100,000 copies/ml, the therapeutic value of the combination rilpivirineemtricitabine-tenofovir (Eviplera) is comparable with that of the combination efavirenzemtricitabine-tenofovir (Atripla).

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.